The person in the advertisement is well and wants to be slimmer. A nationwide Norwegian registry study looked at who actually starts these drugs, matching each of 190,818 initiators to five population controls of the same age and sex and reading their diagnoses from the two preceding years [1]. It is the clinical counterpart to the market question asked in what a GLP-1 actually costs.
Between 71% and 78% of users carried at least one recorded comorbidity, against 49% to 51% of controls, and 19% to 24% carried four or more. Hypertension appeared in 32% to 38% against 17% to 20%. Sleep apnea appeared in 7% to 11% against 2% to 3%. Those ranges are not uncertainty; they are the spread across the five drugs studied, which were semaglutide, liraglutide, tirzepatide, bupropion-naltrexone and orlistat.
Two of the comparisons are about what else people were already taking. Opioids had been dispensed to 24% to 30% of weight-loss drug users in the preceding year against 13% to 15% of controls, and antidepressants to 20% to 24% against 10% to 11%. Roughly double, on both. A population starting a weight drug is a population already carrying pain and already carrying treated mood disorder, at about twice the background rate.
The caution about transferring this to a cash-pay market is important enough to state plainly. Norway has prescription-only access through a public system where seeing a doctor is cheap, so everybody in this study went through a clinician who had their record in front of them. People buying from a telehealth seller reached the drug by a different route, often without anyone seeing their history, and they may be a different population. What the study establishes is that the medical-need picture is far heavier than the cosmetic framing suggests, which is consistent with the off-label finding in who the price filtered out.
If the typical buyer is carrying several conditions and two other prescriptions, the thoroughness of an intake stops being a formality. That is the same reason the gap between an advertised price and a billed one matters, covered in the headline against the bill, and why the share of people who stop within a year, in two thirds stop within a year, is worth reading beside it.